Merrimack Pharmaceuticals Performance
| MACKDelisted Stock | USD 11.96 0.12 1.01% |
The company secures a Beta (Market Risk) of -0.22, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Merrimack Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Merrimack Pharmaceuticals is likely to outperform the market. Merrimack Pharmaceuticals right now secures a risk of 0.0%. Please verify Merrimack Pharmaceuticals skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Merrimack Pharmaceuticals will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Merrimack Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Merrimack Pharmaceuticals is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Begin Period Cash Flow | 19.4 M | |
| Free Cash Flow | -1.5 M |
Merrimack |
Merrimack Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,196 in Merrimack Pharmaceuticals on September 13, 2024 and sell it today you would earn a total of 0.00 from holding Merrimack Pharmaceuticals or generate 0.0% return on investment over 90 days. Merrimack Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Merrimack, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Merrimack Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Merrimack Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Merrimack Pharmaceuticals, and traders can use it to determine the average amount a Merrimack Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MACK |
Based on monthly moving average Merrimack Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Merrimack Pharmaceuticals by adding Merrimack Pharmaceuticals to a well-diversified portfolio.
Merrimack Pharmaceuticals Fundamentals Growth
Merrimack Stock prices reflect investors' perceptions of the future prospects and financial health of Merrimack Pharmaceuticals, and Merrimack Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Merrimack Stock performance.
| Return On Equity | -0.0112 | |||
| Return On Asset | -0.0107 | |||
| Current Valuation | (20.36 M) | |||
| Shares Outstanding | 14.79 M | |||
| Price To Earning | 65.70 X | |||
| Price To Book | 11.38 X | |||
| EBITDA | (2.18 M) | |||
| Cash And Equivalents | 13.36 M | |||
| Cash Per Share | 1.00 X | |||
| Debt To Equity | 33.90 % | |||
| Book Value Per Share | 15.25 X | |||
| Cash Flow From Operations | (1.52 M) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 19.19 M | |||
| Retained Earnings | (548.82 M) | |||
| Current Asset | 89.62 M | |||
| Current Liabilities | 88.28 M | |||
About Merrimack Pharmaceuticals Performance
By examining Merrimack Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Merrimack Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Merrimack Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.Things to note about Merrimack Pharmaceuticals performance evaluation
Checking the ongoing alerts about Merrimack Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Merrimack Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Merrimack Pharmaceuticals is not yet fully synchronised with the market data | |
| Merrimack Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (1.18 M) with loss before overhead, payroll, taxes, and interest of (9.1 M). | |
| Merrimack Pharmaceuticals currently holds about 13.36 M in cash with (1.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0. | |
| Roughly 63.0% of the company shares are owned by institutional investors |
- Analyzing Merrimack Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Merrimack Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Merrimack Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Merrimack Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Merrimack Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Merrimack Pharmaceuticals' stock. These opinions can provide insight into Merrimack Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |